Home › Overweight
Pag-aaral pangklinika para sa Overweight na nagre-recruit sa U.S.
209 pag-aaral para sa Overweight ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- San Antonio, TX34 pag-aaral
- Houston, TX33 pag-aaral
- Chicago, IL29 pag-aaral
- Orlando, FL27 pag-aaral
- Dallas, TX23 pag-aaral
- Miami, FL23 pag-aaral
- Washington, DC20 pag-aaral
- Atlanta, GA20 pag-aaral
- Austin, TX19 pag-aaral
- Las Vegas, NV19 pag-aaral
- Jacksonville, FL19 pag-aaral
- New York City, NY19 pag-aaral
- Los Angeles, CA18 pag-aaral
- Tucson, AZ17 pag-aaral
- Baltimore, MD16 pag-aaral
- Birmingham, AL16 pag-aaral
- St. Louis, MO16 pag-aaral
- Louisville, KY15 pag-aaral
- Charlotte, NC15 pag-aaral
- Concord, CA15 pag-aaral
- Havelock, NC15 pag-aaral
- San Diego, CA14 pag-aaral
- Wilmington, NC14 pag-aaral
- Roswell, GA14 pag-aaral
- Indianapolis, IN14 pag-aaral
- Cincinnati, OH14 pag-aaral
- Phoenix, AZ13 pag-aaral
- Honolulu, HI13 pag-aaral
- Philadelphia, PA13 pag-aaral
- Rochester, NY13 pag-aaral
- Farmington Hills, MI12 pag-aaral
- Columbus, OH12 pag-aaral
- Johns Creek, GA12 pag-aaral
- Nashville, TN12 pag-aaral
- Arlington, VA12 pag-aaral
- Deltona, FL12 pag-aaral
- Escondido, CA11 pag-aaral
- Greensboro, NC11 pag-aaral
- Salt Lake City, UT11 pag-aaral
- The Woodlands, TX10 pag-aaral
Ayos sa estado
- Alabama31 pag-aaral
- Arizona29 pag-aaral
- Arkansas7 pag-aaral
- California69 pag-aaral
- Colorado11 pag-aaral
- Connecticut16 pag-aaral
- District of Columbia7 pag-aaral
- Florida60 pag-aaral
- Georgia38 pag-aaral
- Hawaii13 pag-aaral
- Idaho20 pag-aaral
- Illinois40 pag-aaral
- Indiana18 pag-aaral
- Iowa10 pag-aaral
- Kansas27 pag-aaral
- Kentucky23 pag-aaral
- Louisiana24 pag-aaral
- Maryland36 pag-aaral
- Massachusetts22 pag-aaral
- Michigan21 pag-aaral
- Minnesota11 pag-aaral
- Mississippi12 pag-aaral
- Missouri35 pag-aaral
- Montana6 pag-aaral
- Nebraska6 pag-aaral
- Nevada20 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey13 pag-aaral
- New Mexico5 pag-aaral
- New York44 pag-aaral
- North Carolina40 pag-aaral
- North Dakota8 pag-aaral
- Ohio33 pag-aaral
- Oklahoma18 pag-aaral
- Oregon13 pag-aaral
- Pennsylvania32 pag-aaral
- Rhode Island11 pag-aaral
- South Carolina32 pag-aaral
- South Dakota3 pag-aaral
- Tennessee24 pag-aaral
- Texas57 pag-aaral
- Utah18 pag-aaral
- Virginia34 pag-aaral
- Washington23 pag-aaral
- Wisconsin8 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 60 · Kababaihan · Na-update Nob 12, 2026 · NCT03407079Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain
Nagre-recruit
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07708064Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07830329Time Restricted Eating (TRE) in Bipolar Disorder
Nagre-recruit
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07211217Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07871409A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07351045A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07776509A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07351058Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07685808Metabolic Health, Bones and Nuts During Weight Loss in Adults
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 50 hanggang 75 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06949280Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07575399A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07876531A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07823608A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07845500Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07866066A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07843498A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07843485A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07919678A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07595549Confident Moves Intervention Efficacy Trial: Obesity Care Settings
Nagre-recruit
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07623772A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07881458A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06857942A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07392190Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.